Forensic Toxicology

, Volume 31, Issue 1, pp 93–100

New cannabimimetic indazole derivatives, N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA) and N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA) identified as designer drugs in illegal products

  • Nahoko Uchiyama
  • Satoru Matsuda
  • Daigo Wakana
  • Ruri Kikura-Hanajiri
  • Yukihiro Goda
Original Article

DOI: 10.1007/s11419-012-0171-4

Cite this article as:
Uchiyama, N., Matsuda, S., Wakana, D. et al. Forensic Toxicol (2013) 31: 93. doi:10.1007/s11419-012-0171-4

Abstract

Two new cannabimimetic indazole derivatives, N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA, 1) and N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA, 2), have been identified as designer drugs in illegal products. These identifications were based on liquid chromatography–mass spectrometry, gas chromatography–mass spectrometry, high-resolution mass spectrometry, and nuclear magnetic resonance spectroscopy. Because there have been neither chemical nor pharmacological data about compound 1 until now, this is the first report of this compound. Compound 2 was reported as a potent cannabinoid CB1 receptor modulator when synthesized by Pfizer in 2009; but this is the first report of its detection in illegal products.

Keywords

N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-PINACAN-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA)Synthetic cannabinoidIndazole derivativeDesigner drugIllegal product

Copyright information

© Japanese Association of Forensic Toxicology and Springer Japan 2012

Authors and Affiliations

  • Nahoko Uchiyama
    • 1
  • Satoru Matsuda
    • 1
  • Daigo Wakana
    • 1
  • Ruri Kikura-Hanajiri
    • 1
  • Yukihiro Goda
    • 1
  1. 1.National Institute of Health SciencesTokyoJapan